Rekenbi, an Alzheimer's treatment jointly developed by Japan and the US, has arrived in Japan... Expected to be launched in South Korea in 2025

Rekenbi, a new drug for Alzheimer's disease jointly developed by Japan's Eisai and America's Biogen, has landed on the Japanese market. In South Korea, approval will be obtained in the second half of next year and it will be released the year after next.